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Abstract
Histological analysis of liver biopsies remains a stan-
dard against which other methods of assessment for 
the presence and amount of hepatic injury due to 
nonalcoholic fatty liver disease (NAFLD) are measured. 
Histological evaluation remains the sole method of dis-
tinguishing steatosis from advanced forms of NAFLD, 
i.e. nonalcoholic steatohepatitis (NASH) and fibrosis. 
Included in the lesions of NAFLD are steatosis, lobular 
and portal inflammation, hepatocyte injury in the forms 
of ballooning and apoptosis, and fibrosis. However, 
patterns of these lesions are as distinguishing as the 
lesions themselves. Liver injury in adults and children 
due to NAFLD may have different histological patterns. 
In this review, the rationale for liver biopsy, as well as 
the histopathological lesions, the microscopically ob-
servable patterns of injury, and the differential diagno-
ses of NAFLD and NASH are discussed.
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INTRODUCTION
Liver biopsy evaluation was the foundation for the pro-
posals that certain individuals who do not consume excess 
alcohol could, in fact, suffer from a form of  chronic pro-
gressive liver disease characterized by lesions that had been 
considered those of  alcohol, namely, steatosis, ballooned 
hepatocytes with Mallory-Denk hyaline bodies, and the 
particular form of  fibrosis of  alcohol. Several authors 
had been evaluating this concept[1-5], when the seminal 
manuscript of  Ludwig et al[6] was published in 1980 that 
described 20 subjects. Since that time, much of  the prog-
ress that has been made in studies of  natural history[7-12], 
clinical associations of  histological assessments of  activity 
and fibrosis, correlations with metabolic syndrome[13,14] 
and serum markers of  cardio-vascular disease[15], the vari-
ability of  ethnic susceptibility[16-18], and the presence of  
hepatocellular carcinoma in cirrhotics and non-cirrhotics 
with nonalcoholic fatty liver disease (NAFLD)[19-21] have 
occurred by evaluating liver biopsies.
The clinical and scientific needs for imaging stud-
ies and serum-based assays to “predict” the presence of  
steatohepatitis, fibrosis, and/or inflammation are based 
on a well-recognized concept that liver biopsy is invasive, 
potentially harmful, and may suffer from “sampling er-
ror”[22,23]. Furthermore, liver biopsy cannot be considered 
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a screening tool for population studies. However, it is also 
recognized that, imperfect as it is, liver biopsy evaluation 
remains the standard against which other assays and clini-
cal algorithms must be matched, and prospectively vali-
dated. 
Liver biopsy does, indeed, suffer from challenges. 
Many can be overcome by the realization that even an ad-
equate biopsy represents only 1/50 000-1/65 000 of  this 
large organ. Therefore, high quality biopsy techniques, 
such as utilization of  appropriately sized needles[24], care-
ful choice of  sampled area, and appropriate tissue prepa-
ration and interpretation are all important considerations 
for liver biopsy. Pathologists recognize that wedge biop-
sies are inferior to appropriately-sized and placed needle 
core biopsies for evaluation of  a diffuse parenchymal 
disease. In addition, there might be differences between 
right and left lobes of  the liver, as the left lobe is relatively 
smaller, is covered by more capsule per unit area, and the 
subcapsular portal tracts can be deceptively more fibrous 
than those of  deeper parenchyma. Differences in histo-
pathological findings have been demonstrated in studies 
of  bariatric patients biopsied concurrently from the right 
and left lobes[25]; these differences were abrogated some-
what by the use of  a large bore needle in another study[24]. 
Adequate sample length has also been noted as a correla-
tive factor with histological evaluation in NAFLD[26], with 
biopsies ≥ 1.5 cm long having a higher yield of  definitive 
nonalcoholic steatohepatitis (NASH) diagnosis compared 
to those measuring < 1 cm in length (29% vs 56%)[26]. 
Small biopsies (< 1.6 cm) show higher variability for 
NAFLD fibrosis stage than longer biopsies[27]. It has been 
proposed that sampling error might be reduced by using 
larger gauge needles[24], obtaining longer (≥ 1.5 cm) biop-
sies[28], or by taking more than one tissue core when pos-
sible[26]. Once in the laboratory, liver biopsies should not 
be prepared on tissue “sponges”, as these create space-
distorting artifacts[29]. Of  at least equal, if  not greater, 
significance, however, is pathologists’ training and focus 
in the field. Just as one doesn’t ask a non-specialized sur-
geon to perform cardiac bypass surgery, one should also 
recognize the need for trained liver pathologists. Studies 
in chronic hepatitis C (CHC) liver biopsy evaluation that 
compared the expertise of  liver pathologists in academic 
practice with community pathologists showed this to be 
a potential source of  discordance in histological evalu-
ation[30]. The number of  independent readings has also 
been shown to correlate with greater yield of  findings[26]. 
VALUE OF LIVER BIOPSY EVALUATION 
IN NONALCOHOLIC FATTY LIVER 
DISEASE
Pro’s and Con’s of liver biopsy
The large series of  over 350 liver biopsies done for clini-
cally unexplained liver test elevation in adults by Skelly 
et al[31] highlights the value of  liver biopsy evaluation in this 
setting. While two-thirds of  the biopsies showed some 
form of  nonalcoholic fatty liver disease, the remainder 
were either “normal” (6%) or had histopathological fea-
tures of  subsequently clinically confirmed liver disease, 
such as hereditary hemochromatosis, drug-induced liver 
injury, and autoimmune liver disease. Several series have 
now shown the lack of  correlation of  alanine aminotrans-
ferase (ALT) levels and both necroinflammatory activity 
and fibrosis, including cirrhosis, in subjects with known 
NAFLD[32-34], including obese children[35]. Liver biopsy 
evaluation is also important for a patient with a clinical 
suspicion of  autoimmune liver disease. Up to 20% of  
NAFLD have positive serologies for antinuclear antibody, 
antismooth muscle antibody, and/or antimitochondrial 
antibody[36-38]; therefore, liver biopsy evaluation might be 
the only means of  determining the underlying cause of  
the disease. Furthermore, surgeons have shown that intra-
operative visualization is commonly not correct for the 
prediction of  either steatosis or advanced fibrosis, and thus 
liver biopsy is currently being recommended in the mor-
bidly obese bariatric population at the time of  surgery[39].
The final “pro” of  liver biopsy is both confirmation 
of  the diagnosis, as well as evaluation and semiquanti-
tation of  necroinflammatory lesions and fibrosis, and 
evaluation of  architectural remodeling. To date, nonin-
vasive tests have shown to be effective for the extremes: 
either lack of, or abundance of, inflammation or fibrosis, 
but overall sensitivity and specificity for the lesions in 
between are less impressive[22]. A recently studied modi-
fication of  the European Liver Fibrosis score, named 
the Enhanced Liver Fibrosis score, has shown the most 
promise in terms of  predicting over 75% of  adult pa-
tients who would not need a liver biopsy, regardless of  
stage[40]. Measurement of  serum keratin 18 (K18) frag-
ments, a marker of  hepatocyte apoptosis, has emerged 
as a promising biomarker for NASH, with sensitivity 
and specificity of  up to 77% and 92%, respectively[41]. 
Transient elastography measuring liver stiffness has been 
recently shown to be a useful noninvasive test to exclude 
advanced fibrosis in Chinese NAFLD patients, with a 
negative predictive value of  97%[42]. Limitations and 
need for further testing of  this modality are reviewed[43].
The arguments against liver biopsy in NAFLD in-
clude the invasive nature of  the procedure, the lack 
of  effective treatments beyond recommendations for 
dietary changes, weight loss and exercise, the fact that 
only a minority of  NAFLD patients have the progres-
sive lesions of  NASH[44], and the known improvements 
of  diagnosis with clinically-derived tests[45,46] and imaging 
techniques[47]. However, at present, the final correlation 
for any of  the new tests is liver biopsy evaluation. 
HISTOLOGY OF NAFLD IN ADULTS
The histological spectrum of  NAFLD includes various 
forms of  small and large droplet macrovesicular ste-
atosis, with or without lobular and portal inflammation, 
and steatohepatitis, which is characterized by steatosis, 
inflammation, and cell injury, i.e. NASH. Progression 
of  fibrosis and architectural remodeling is thought to 
develop in 10%-15% of  NASH patients, and cirrhosis 
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in 15%-25%. Thus, of  all individuals with some form(s) 
of  fatty liver, 3%-5% may develop cirrhosis[48]. Cirrhosis 
due to NASH and cryptogenic cirrhosis might both re-
sult in hepatocellular carcinoma (HCC)[19,49]. Rarely, HCC 
may occur in non-cirrhotic NASH[21,50].
NAFLD
The main histological characteristic of  NAFLD, as its 
name implies, is the accumulation of  fat in the form of  
triglycerides within hepatocytes, a lesion originally termed 
“steatosis” after the ancient Greek word for fat, “stear”. 
The presence of  > 5% steatotic hepatocytes in a liver tis-
sue section is now accepted as the minimum criterion for 
the histological diagnosis of  NAFLD[51,52]. 
Steatosis in NAFLD is usually macrovesicular, refer-
ring to hepatocytes with a single large intracytoplasmic fat 
droplet or smaller well defined droplets displacing the nu-
cleus to the cell periphery. Mixed steatosis might also oc-
cur, when, in addition to macrovesicular steatosis, groups 
of  hepatocytes with centrally placed nuclei and numerous 
minute lipid droplets in the cytoplasm are observed. Pure 
microvesicular steatosis, needing special stains such as Oil-
Red-O to identify the intracytoplasmic material as fat, is 
not a common feature of  NAFLD; however, small, azonal 
collections of  hepatocytes might have this type of  fat. In 
simple NAFLD, in addition to steatosis, foci of  lobular 
inflammation, mild portal inflammation, and lipogranulo-
mas may be seen. However, features of  hepatocellular in-
jury and fibrosis, indicating progression to steatohepatitis, 
are not observed, by definition[51].
The extent of  steatosis is commonly evaluated and re-
ported semi-quantitatively. The most reproducible method 
follows the acinar architecture dividing the liver paren-
chyma in thirds and assessing percentage involvement by 
steatotic hepatocytes: 0%-33% (or 0%-5%, 5%-33%)-mild, 
33%-66%-moderate or > 66% - severe steatosis[53,54].
One of  the distinctive features of  steatosis in adult 
NAFLD, in contrast to most pediatric NAFLD cases, is its 
predilection to start in acinar zone 3 (perivenular). When 
steatosis is severe it can occupy the whole acinus. Steatosis 
might not persist during the progression of  fibrosis to 
remodeling and cirrhosis; thus, steatosis might not be reli-
ably identified in a cirrhotic liver[55]. 
Adult NASH
Most hepatopathologists agree that the minimal criteria 
for the histological diagnosis of  adult NASH include ste-
atosis, hepatocyte injury, usually in the form of  balloon-
ing, and lobular inflammation, typically localized in acinar 
zone 3. Fibrosis, as in other forms of  chronic hepatitis, is 
not a required diagnostic feature of  NASH[56-58]. 
Hepatocellular injury in NASH can take the form of  
ballooning, apoptosis, or lytic necrosis[51]. Ballooning is a 
feature of  major importance in NASH as its presence has 
been associated in prognostic studies with more aggressive 
disease and high incidence of  cirrhosis[59]. Furthermore, 
the presence of  ballooned hepatocytes on liver biopsy has 
been linked with features of  the metabolic syndrome[60]. 
Ballooned hepatocytes are enlarged, with swollen, rarefied, 
pale cytoplasm and, usually, show a large, hyperchromatic 
nucleus, often with a prominent nucleolus. They might 
be the result of  alterations in intermediate filament cyto-
skeleton[61] and/or presence of  microvesicular steatosis[62]. 
The histological recognition of  hepatocellular ballooning 
can show significant inter-observer variation[63]. Loss of  
the normal hepatocyte keratins, 8 and 18, as detected by 
immunostaining, might help in the objective identification 
of  ballooned hepatocytes[64]. 
Apoptotic (acidophil) bodies, another form of  he-
patocyte injury and a feature of  programmed cell death, 
are common in NASH[65]. They can easily be identified 
on routine stains, but are further highlighted by immu-
nohistochemistry for keratin 18 fragments, the same an-
tigen that has been recently proposed as a biomarker of  
NASH[41,66]. The number of  acidophil bodies per mm2 of  
liver tissue (acidophil body index) has been proposed to 
serve as a complementary histological feature when diag-
nosis of  NASH is uncertain[67]. 
Lobular inflammation is usually mild, and consists of  a 
mixed inflammatory cell infiltrate, composed of  lympho-
cytes, some eosinophils, and, occasionally, a few neutro-
phils. Polymorphs are occasionally observed surrounding 
ballooned hepatocytes in a lesion known as “satellitosis”. 
Foci of  chronic lobular inflammation, consisting mainly 
of  lymphocytes, are occasionally seen. Scattered lobular 
microgranulomas (Kupffer cell aggregates) and lipogranu-
lomas are common[57,68].
Portal chronic mononuclear cell inflammation in adult 
NASH is not uncommon and is usually mild. When severe 
or disproportionate to the acinar lesions, the possibility of  
concurrent CHC should be excluded[56,68,69]. In untreated 
NAFLD patients, increased portal inflammation has been 
proposed as a marker of  severe disease[70], and has been 
correlated with the diagnosis of  definite steatohepatitis[71].
Fibrosis in adult NASH usually starts in acinar zone 3 
and has a characteristic “chicken wire” pattern due to de-
position of  collagen and other extracellular matrix fibers 
along the sinusoids of  zone 3 and around the hepatocytes. 
Portal fibrosis without perisinusoidal/pericellular fibrosis 
has been reported in some cases of  morbid obesity-relat-
ed NASH[72,73] and in pediatric NASH (discussed below). 
In advanced disease, bridging fibrosis and cirrhosis might 
develop[51]. NASH-related cirrhosis is most commonly 
macronodular or mixed. At the cirrhotic stage, perisinu-
soidal fibrosis and other features of  “active” disease may 
or may not be evident. Therefore, in the absence of  a pre-
vious biopsy with NASH or other disease-specific histolo-
gy, the cirrhosis may be labeled “cryptogenic”. In a recent 
meta-analysis of  ten longitudinal histological studies of  
NASH, presence of  inflammation in the initial biopsy and 
age emerged as independent predictors of  progression to 
advanced fibrosis in patients with NASH[74].
Sinusoidal collagen formation in NASH, as in other 
chronic liver diseases, is likely to be the result of  hepatic 
stellate cell (HSC) activation[75,76]. The HSC activation 
score, as measured by alpha-smooth muscle actin im-
munohistochemistry, was shown to predict progression 
of  fibrosis in NAFLD[77]. Portal fibrosis, on the other 
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hand, has been linked to the ductular reaction (i.e. ductu-
lar proliferation at the portal tract interface arising from 
progenitor cells in the periportal area and accompanied 
by neutrophils and stromal changes). These findings have 
been correlated with insulin resistance, impaired hepa-
tocellular replication, and advanced stages of  fibrosis, 
indicating that it might provide a pathway for progressive 
fibrosis[78]. Recent work has found evidence of  epithelial-
to-mesenchymal transition of  ductular cells via activation 
of  the hedgehog pathway, a process by which mature 
epithelial cells differentiate into cells with a mesenchymal 
phenotype and function, in NAFLD[79]. 
Other histological lesions that may be seen in NASH 
include Mallory-Denk bodies (MDB), megamitochondria, 
glycogenated nuclei, and iron deposition. MDB (previously 
called Mallory bodies or Mallory’s hyaline)[61] are eosino-
philic intracytoplasmic inclusions commonly seen close to 
the nucleus of  ballooned hepatocytes in zone 3, usually 
in areas of  perisinusoidal fibrosis. They are composed of  
misfolded intermediate filaments (keratins 8 and 18), ubiq-
uitin, heat shock proteins, and p62[80]. MDB have been 
correlated with increased necroinflammatory activity[53] 
and with a higher incidence of  cirrhosis[59]. Although not 
a requirement for the histological identification of  NASH, 
the presence of  MDB strengthens the diagnosis. MDB are 
not, however, restricted to NASH and can be seen in ste-
atohepatitis due to other causes (alcoholic, drug-induced, 
etc), as well as in chronic cholestasis, metabolic diseases, 
and hepatocellular neoplasms[81]. 
Megamitochondria (giant mitochondria) are round or 
needle-shaped, eosinophilic, intracytoplasmic inclusions 
more commonly observed in hepatocytes with microve-
sicular steatosis. The are not zonally restricted[82]. Ultra-
structural studies have shown that these abnormal mito-
chondria show loss of  cristae, multilamellar membranes, 
and paracrystalline inclusions[82,83]. Megamitochondria in 
NASH may be the result of  injury from lipid peroxidation 
or represent an adaptive change[84]. Glycogenated nuclei 
are vacuolated nuclei usually observed in periportal he-
patocytes. Their presence in biopsies with steatohepatitis 
is supportive of  nonalcoholic etiology (obesity and/or 
diabetes) because they are very rarely seen in biopsies of  
alcoholic steatohepatitis (ASH)[85]. 
Finally, hepatic siderosis might be seen in NAFLD 
biopsies. It is usually mild (1+, 2+) and occurs in peri-
portal hepatocytes and/or pan-acinar reticulo-endothelial 
cells. The significance of  liver tissue iron deposition and 
abnormal iron metabolism genetics in the pathogenesis 
and progression of  NAFLD are under investigation[86,87]. 
HISTOLOGY OF NAFLD IN ADULTS: 
PATHOLOGIST REPRODUCIBILITY
Reproducibility studies have shown excellent to good 
agreement for the extent of  steatosis, presence of  perisi-
nusoidal fibrosis, and stage of  fibrosis in adult NAFLD; 
the feature with the least agreement between histopathol-
ogists is lobular inflammation[54,88,89]. Intra-observer agree-
ment is generally better than inter-observer agreement for 
all histological features and diagnostic categories. 
HISTOLOGICAL FINDINGS OF NAFLD/
NASH IN CONCURRENCE WITH OTHER 
LIVER DISEASE
The increased frequency of  NAFLD in the general popu-
lation makes it important for pathologists to recognize the 
lesions, especially those of  NASH, when concurrent with 
other clinically suspected liver diseases. The frequency of  
co-existent NASH in a series of  > 3000 non-allograft liver 
biopsies undertaken for clinical suspicion of  CHC, auto-
immune hepatitis, hemochromatosis, alpha-1-antitrypsin 
deficiency, or chronic hepatitis B was 2.6%[90]. This num-
ber most likely underestimates the actual prevalence of  
the concurrence given the very stringent criteria for the 
diagnosis of  SH used in the study[56]. Other groups, how-
ever, have found similar results[91].
In CHC, which is the most common chronic liver dis-
ease diagnosed with concomitant NASH (5%-10%)[90-93], 
the presence of  NAFLD can accelerate disease progres-
sion and decrease response to antiviral treatment with 
negative consequences on patients’ prognoses[94,95]. Other 
studies have shown that co-existent fatty liver or NASH in 
CHC, more common in patients with genotype 3, was not 
related to metabolic disturbances[93]. In a subsequent study, 
however, this same group showed that insulin resistance 
was increased in CHC, particularly genotypes 1 and 4, and 
was independently related to advanced fibrosis[94]. Thus, 
the data for CHC and NAFLD is still under investigation.
The diagnosis of  concurrent NASH can be a chal-
lenge. One study required the identification of  the char-
acteristic zone 3 perisinusoidal fibrosis[90], as this is not 
a typical finding in other forms of  chronic liver disease; 
another study only required the prominence of  steatosis 
and inflammation in zone 3, along with hepatocellular 
ballooning[93]. It is important to understand that hepato-
cellular ballooning, steatosis, and even MDB, have been 
documented in CHC[96].
Recently, the co-existence of  NAFLD and alcoholic 
liver disease (ALD) has been increasingly recognised in 
clinical settings. The presence of  NAFLD in alcoholic pa-
tients has been linked with progression of  ALD[97], while 
some have shown that moderate alcohol consumption is 
associated with fibrosis progression in NAFLD[98]. Inter-
estingly, in contrast, several studies have shown a benefi-
cial effect of  moderate alcohol intake. Moderate alcohol 
use was shown to be protective against insulin resistance 
in morbidly obese individuals[73], was associated with de-
creased prevalence of  fatty liver in asymptomatic individu-
als[99], and with decreased prevalence of  steatohepatitis in 
NAFLD patients[100]. The pathologist is not able to recog-
nize the relative contributions of  NAFLD or ALD to the 
liver injury in a biopsy with steatohepatitis. 
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HISTOLOGICAL FINDINGS OF 
RESOLUTION OF NASH
Resolution of  the histological lesions of  NASH is one 
of  the primary end-points of  many treatment trials. It is 
now apparent that “spontaneous” resolution of  liver in-
jury can occur without treatment (i.e. studies of  placebo 
groups)[101-103]. This observation, therefore, indicates the 
need for adequate sample size as well as randomized 
controlled trial for treatment trials of  NASH.
Improvement of  the major histological features of  
disease activity (i.e. steatosis, lobular inflammation, and 
ballooning), grade of  steatohepatitis and, occasionally, of  
fibrosis following therapy using different agents, including 
thiazolidinediones (pioglitazone and rosiglitazone), metfor-
min, vitamins E and C, dietary interventions, or bariatric 
surgery have been reported[104]. However, after discontinu-
ation of  medical treatment, the initial histological improve-
ment might not be maintained, indicating the need for 
longer (permanent?) duration of  therapy[105]. Nevertheless, 
the results of  one long-term treatment trial with the insulin 
sensitizer roziglitazone showed that there is no additional 
anti-steatogenic effect with longer treatment, despite an in-
crease in insulin sensitivity[106]. In contrast, reportedly, sur-
gical intervention for obesity appears to have long-lasting 
beneficial effects on liver histology[107,108].
Histological evaluation of  post-treatment liver bi-
opsies in a small trial[102] showed that increased portal 
inflammation is a feature related to resolution of  NASH; 
a subsequent review of  published treatment trials has con-
firmed this finding, which is independent of  the type of  
therapeutic intervention (medical, dietary, or surgical)[56]. 
In some cases, successful treatment with resolution is as-
sociated with the change in the quality of  zone 3 perisinu-
soidal fibrosis from dense to delicate[102]. 
HISTOLOGY OF NAFLD IN PEDIATRIC 
SUBJECTS
Diagnosis of  nonalcoholic fatty liver disease in children 
continues to be a challenge for pathologists. Clinico-
pathological studies have confirmed that the lesions may 
or may not resemble those of  adults, including cirrhosis 
with and without steatosis and inflammation[109-119].
Utilizing a mathematic algorithm of  the lesions fol-
lowing evaluation of  100 obese children and their liver bi-
opsies, Schwimmer et al[120] proposed the currently utilized 
schema of  types 1 and 2 steatohepatitis in pediatric fatty 
liver disease. Type 1, the least common overall, but the 
most common in girls, resembles the adult pattern, with 
zone 3 accentuation of  steatosis. Type 2 is more common 
in boys, and consists of  either zone 1 accentuation of  
steatosis, or panacinar steatosis. Ballooning was uncom-
mon in both types. Zone 3 perisinusoidal fibrosis was 
uncommon in type 2, whereas, when fibrosis was pres-
ent, only portal-based fibrosis was seen. A small percent 
of  cases did not fit completely into either category in the 
Schwimmer study, and were referred to as “overlap”. A 
subsequent clinicopathological series from children from 
a single site in Rome[112], as well as multiple centers across 
North America[115], have found types 1 and 2 less common 
than overlap patterns, and individual features such as zone 
3 steatosis, ballooning, and zone 3 perisinusoidal fibrosis 
less common in children than in adults[121]. However, no 
author has yet specified the features and/or patterns of  
injury that would result in an unequivocal diagnosis of  
“steatohepatitis” in pediatric cases if  there were changes 
other than the adult-pattern. Thus, this is an area of  on-
going investigation in pathology. In addition, there are 
no natural history studies to date showing evolution of  
the pediatric pattern in children; whether it evolves to the 
adult pattern with increasing age or not is unknown. The 
rate and processes involved in progression to cirrhosis, an 
unfortunate but growing problem[114] in obese children, 
are also unknown. 
HISTOLOGY OF NAFLD IN SPECIAL 
POPULATIONS
Asians
It is recognized that the body habitus of  individuals of  
Asian descent differs from that of  Caucasoids; there is 
greater body fat for a given body mass index (BMI) in 
Asians[122], thus, the prevalence and incidence of  NAFLD 
and advanced fibrosis are related to factors other than 
BMI. However, histological features, as described, do 
not appear to differ from those described for Caucasian 
adults.
Bariatric patients
To date, there is no dedicated literature related to the bar-
iatric population, other than straightforward observations 
of  changes of  steatosis, inflammation, and fibrosis fol-
lowing surgery. Many studies are done without a specific 
protocol requiring follow-up biopsies, and most workers 
do not require pre and post biopsies to be obtained from 
the same lobe of  the liver, or for surgical biopsies to be 
obtained as early as possible in the operation to avoid 
the accrual of  polymorphonuclear leukocytes within the 
lobules (i.e. surgical hepatitis). The former is important 
because of  potential differences between the lobes (cap-
sule: parenchyma ratio) and the latter for obtaining cor-
rect lobular inflammation scores. The extant literature is 
reviewed[108] and highlights the fact that the majority of  
bariatric patients have varying amounts of  steatosis. In ad-
dition, a recent study of  surgeon ability to detect steatosis 
and/or cirrhosis has shown that this is not reproducible; 
thus reinforcing the need for liver biopsy in all bariatric 
patients[123]. To this, the authors would add unpublished 
personal observations of  the non-cirrhotic biopsies from 
bariatric surgery, that (1) it is common to see enlarged, 
prominent portal tracts from biopsies obtained from the 
left lobe; (2) steatosis is commonly mild and often not in 
zone 3; and (3) zone 3 perisinusoidal fibrosis is uncom-
mon. It is possible that the very low calorie diet that com-
monly precedes the actual surgical procedure influences 
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NAFLD and even NASH that may have been present. 
Finally, a large European study has shown that after five 
years, if  insulin resistance has not improved, fibrosis 
might actually show progression[124].
NASH IN THE TRANSPLANTED LIVER 
NAFLD can occur in the allograft liver as recurrence or 
as a de novo process[125-136]. 
The incidence of  recurrent steatosis in patients trans-
planted for cryptogenic cirrhosis or NASH-cirrhosis 
ranges from 25%-100%, while NASH development is 
observed in 10%-37.5% of  these cases without leading to 
early allograft failure (reviewed in[135]). Recurrent NASH 
can progress to advanced fibrosis and cirrhosis, but only 
rare cases have been re-transplanted as a result of  decom-
pensation due to severe NASH in the allograft[137].
Development of  de novo steatosis and/or NASH in the 
liver allograft might be the result of  metabolic disturbanc-
es, as transplanted patients are at increased risk for obesity, 
diabetes, hypertension, and hypercholesterolemia and have 
decreased physical activity levels. Moreover, anti-rejection 
medications, in particular steroid treatment and cyclospo-
rine, are known risks for fatty liver development in the al-
lograft, probably by affecting diabetogenic pathways[51,138]. 
Therefore, the occurrence of  NASH in an allograft liver 
of  a patient transplanted for “cryptogenic cirrhosis” does 
not justify attribution of  the original disease to “burned-
out” NASH without appropriate clinico-pathological cor-
relation[139-141].
DIFFERENTIAL DIAGNOSIS
Clinico-pathological correlation is essential for highlight-
ing the underlying cause of  steatohepatitis in a liver bi-
opsy, as the histology is similar irrespective of  etiology. 
The differential diagnoses of  NAFLD and NASH include 
ASH, drug toxicity (tamoxifen, glucocorticoids, and highly 
active antiretroviral therapy in human immunodeficiency 
virus patients), metabolic diseases (such as Wilson disease, 
tyrosinemia, and citrin deficiency), lipodystrophy, surgical 
procedures (such as jejunoileal bypass and biliopancreatic 
diversion), total parenteral nutrition, and malnutrition[51]. 
ASH vs NASH
The ongoing discussions of  the limits of  alcohol in-
take in “nonalcoholic” fatty liver[142] revolve around the 
complex interactions of  host (genetic and metabolic) 
factors[143,144], the type of  alcohol utilized, patterns of  
drinking[144], and the potentially beneficial interactions of  
modest alcohol with insulin resistance[73]. 
Hepatopathologists agree that the histology of  un-
complicated NAFLD and alcoholic steatosis are indis-
tinguishable. Further, NASH might be indistinguishable 
from ASH; however, there are some histological features 
observed in ALD that have not yet been described in 
NAFLD. These include sclerosing hyaline necrosis (a 
combination of  dense perivenular fibrosis, MDB accumu-
lation, and hepatocyte necrosis in zone 3), veno-occlusive 
lesions, alcoholic foamy degeneration (zone 3 microve-
sicular steatosis), and cholestasis[51]. Generally, there is 
consensus that the overall histopathological appearance of  
NASH is milder than that observed in ASH[145], with the 
understanding that alcoholic steatosis can be as “mild” as 
NAFLD. 
Certain histological lesions, including severe steato-
sis, glycogenated nuclei, and lipogranulomas, are more 
frequent in NAFLD compared to ALD; however, their 
utility in differential diagnosis on an individual basis is lim-
ited[145]. On the other hand, numerous, well formed MDB 
and dense fibrosis, composed mostly of  collagen type Ⅲ 
might be indicative of  an alcoholic rather than metabolic 
origin[146-148]. One group utilized immunohistochemical 
detection of  the insulin receptor (IR) and increased ex-
pression of  protein tyrosine phosphatase 1B (PTP1B), a 
protein that acts as a negative regulator of  IR expression, 
to aid in the histological distinction of  ASH and NASH. 
IR receptor was more frequent in NASH in contrast to 
normal expression for IR in conjunction with low level 
expression of  PTP1B noted in ASH[149]. The clinical utility 
of  this method, however, has not been tested. The same 
group also proposed a noninvasive model for the differen-
tial diagnosis between ALD and NAFLD using the ALD/
NAFLD Index (ANI). This is based on the mean cor-
puscular volume, aspartate aminotransferase (AST)/ALT 
ratio, BMI and gender. An ANI greater than 0 indicates 
ALD, while ANI less than 0 is diagnostic of  NAFLD[150]. 
There has been no published validation of  this test.
GRADING AND STAGING OF THE 
HISTOLOGICAL LESIONS IN NAFLD
The first system for grading necroinflammatory activ-
ity and staging fibrosis in NASH appeared in 1999[53] in 
response to the growing need for standardization of  the 
histological criteria used for the diagnosis of  NASH and 
its differentiation from steatosis, and to meet the necessity 
for the development of  a histological scoring system simi-
lar to those already used for other forms of  chronic hepa-
titis. In this scoring system, the features that were shown 
to contribute the most to the severity of  the disease, such 
as steatosis, lobular and portal inflammation, and hepa-
tocellular ballooning were semi-quantitatively assessed 
to produce a three-tier global grade of  activity (Table 1). 
Staging was based on the characteristic pattern and evo-
lution of  fibrosis in NASH with initial involvement of  
perisinusoidal spaces in zone 3 (stage 1) and subsequent 
development of  portal/periportal fibrosis (stage 2), bridg-
ing fibrosis (stage 3), and cirrhosis (stage 4) (Table 1)[53]. 
Among subsequently published scoring systems 
for grading histological activity in NAFLD[54,151] and 
NASH[152], the current most widely used histological scor-
ing system is the one published in 2005 by the NASH 
Clinical Research Network (CRN), sponsored by the 
National Institute of  Diabetes, Digestive and Kidney Dis-
eases[54]. The NASH CRN system has several advantages: 
it is a validated system created from blinded reviews by 
nine pathologists, it is applicable to the entire histological 
Brunt EM et al . Histopathological lesions, nonalcoholic fatty liver disease
5291 November 14, 2010|Volume 16|Issue 42|WJG|www.wjgnet.com
spectrum of  NAFLD, it scores both adult and pediatric 
NAFLD biopsies, and it generates a numeric score for 
grading activity and NAFLD activity score (NAS) for 
comparing pre- and post-treatment biopsies in therapeutic 
trials. The NAS derives from the summation of  individual 
scores for steatosis, lobular inflammation, and hepatocel-
lular ballooning and ranges from 0 to 8 (Table 2). In the 
validation study, NAS of  1 or 2 corresponded to definitely 
not NASH, while a NAS score 5-8 correlated with definite 
NASH. Activity scores 3 and 4 were noted in borderline 
cases that did not fulfill the pathologists’ criteria for defi-
nite NASH. It is important to note, however, that the 
numbers generated by NAS were not created to be used 
as a substitute for histological diagnosis; properly utilized, 
the NAS is applied by the pathologist after reaching final 
diagnosis.
Fibrosis scoring with the NASH CRN system is based 
on the prototype staging method proposed by Brunt 
et al[53], with the difference that stage 1 is further subdivid-
ed into three sub-stages to differentiate between delicate 
perisinusoidal zone 3 fibrosis (stage 1a), dense perisinu-
soidal zone 3 fibrosis (stage 1b), and portal fibrosis only 
(stage 1c)[54]. NASH CRN stage 1c refers to the pattern 
of  fibrosis sometimes seen in severely obese patients and 
in pediatric NASH (Table 2). The value of  histological 
scoring systems for grading and staging in NAFLD in 
routine practice has not yet been adequately assessed and, 
to date, they are mainly used in treatment trials and in 
natural history studies. Furthermore, the recognition of  
the significance of  other histological features associated 
with definite NASH and advanced fibrosis, such as portal 
chronic inflammation[70], and the proposed use of  serum 
biomarkers of  hepatocyte apoptosis for risk-stratifying 
patients with NAFLD[41], indicate that the currently used 
systems could be improved by including these histological 
features in the semi-quantitative histological scoring of  
both adult and pediatric NAFLD[58].
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